Ocular Therapeutix, Inc. ( NASDAQ:OCUL – Get Free Report ) has been given a consensus recommendation of “Moderate Buy” by the seven brokerages that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company.
The average twelve-month price target among brokers that have issued a report on the stock in the last year is $16.71. A number of research analysts recently weighed in on the stock.
HC Wainwright raised their price target on shares of Ocular Therapeutix from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Friday, November 15th.
Robert W. Baird decreased their price objective on shares of Ocular Therapeutix from $18.00 to $17.
00 and set an “outperform” rating for the company in a report on Thursday, August 8th. Finally, Scotiabank initiated coverage on shares of Ocular Therapeutix in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $22.
00 price objective for the company. Check Out Our Latest Analysis on OCUL Ocular Therapeutix Stock Up 7.3 % Hedge Funds Weigh In On Ocular Therapeutix Large investors have recently modified their holdings of the business.
Atlas Capital Advisors LLC purchased a new position in shares of Ocular Therapeutix in the second quarter worth about $34,000. Amalgamated Bank increased its stake in shares of Ocular Therapeutix by 37.9% in the second quarter.
Amalgamated Bank now owns 5,384 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 1,481 shares in the last quarter. Mirae Asset Global Investments Co. Ltd.
increased its stake in shares of Ocular Therapeutix by 22.0% in the third quarter. Mirae Asset Global Investments Co.
Ltd. now owns 5,639 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 1,015 shares in the last quarter. Algert Global LLC purchased a new position in shares of Ocular Therapeutix in the second quarter worth about $69,000.
Finally, Capital Performance Advisors LLP purchased a new position in shares of Ocular Therapeutix in the third quarter worth about $70,000. Hedge funds and other institutional investors own 59.21% of the company’s stock.
About Ocular Therapeutix ( Get Free Report Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. See Also Five stocks we like better than Ocular Therapeutix Most active stocks: Dollar volume vs share volume Cerence Up 155% in 2 Days: SoundHound AI’s Fierce Competitor What is a support level? Why Warren Buffett Is Selling: A Look at His Latest Market Moves What Do S&P 500 Stocks Tell Investors About the Market? Why Amazon Shares May Never Trade Below $200 Again Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.
com's FREE daily email newsletter ..
Business
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Recommendation of “Moderate Buy” from Analysts
Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the seven brokerages that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price [...]